AMAG Pharmaceuticals (NASDAQ:AMAG) traded at a new 52-week high today of $52.92. Approximately 532,000 shares have changed hands today, as compared to an average 30-day volume of 781,000 shares.
AMAG Pharmaceuticals, Inc., a biopharmaceutical company, utilizes its proprietary nanoparticle technology for the development and commercialization of therapeutic iron compounds to treat anemia and novel imaging agents to aid in the diagnosis of cancer and cardiovascular disease.
In the past 52 weeks, AMAG Pharmaceuticals share prices have been bracketed by a low of $16.49 and a high of $52.92 and are now at $51.28, 211% above that low price. Over the past week, the 200-day moving average (MA) has gone up 2.7% while the 50-day MA has advanced 1.9%.
AMAG Pharmaceuticals (NASDAQ:AMAG) defies analysts with a current price ($51.28) 0.1% above its average consensus price target of $51.25. The stock should find initial support at its 50-day moving average (MA) of $44.40 and further support at its 200-day MA of $30.85.